Bayer’s Alok Kanti On Price Cuts And Lower-tier Markets In China: An Interview With PharmAsia News
This article was originally published in PharmAsia News
In his first public interview since assuming leadership for Bayer Healthcare China in July, Alok Kanti discusses Bayer’s strategy in China.
You may also be interested in...
SHANGHAI - China could serve as the catalyst for a new model of dealmaking that emphasizes more flexible and strategic partnerships to drive R&D productivity, but only if Big Pharma is willing to take "calculated risks," according to Bayer Healthcare AG Chairman Jorg Reinhardt
With Latest Round Of Cuts, China Continues March To Narrow Gap Between Big Pharma And Local Generics
SHANGHAI - As expected, China's powerful National Development and Reform Commission announced Aug. 5 a new round of price cuts, this time targeting hormone and endocrinology drugs and central nervous system drugs, with an average cut of roughly 14%, according to analysts
BEIJING - German pharmaceutical powerhouse Bayer Schering is engineering an alliance with Chinese scientists to create a global research and development center in Beijing, according to senior Bayer executives